Semiannual Report — FY2026 H1
What SymBio Pharmaceuticals Limited reported for the period from 2026-01-01 to 2026-12-31.
Filed 2026-08-10View the original on EDINET
How much it says
60Detailed
What moved here
23named for the first time
Its own wording
38terms
Which filing this is
37/ 37newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim consolidated accounting period, patient enrollment progressed in both BCV's global Phase III trial for adenovirus infection following hematopoietic stem-cell transplantation and the NIH-led Phase II trial for PML, while the IVD business advanced partnering discussions toward commercialization based on jointly filed patents. Revenue declined, affected by factors including drug-price revisions, while operating loss and interim net loss widened due in part to higher R&D expenses.
Komori's summary of this document, not the document's own words.60Detailed
How much this filing saysA weighted roll-up of 10 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 33 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
38
Thin
60
Detailed
50
Typical
100
Very detailed
68
Detailed
71
Detailed
7
Almost nothing
79
Very detailed
50
Typical
R&D spend30億円Money spent making new things.
Cash left over-25億円Cash from the business, less what went into equipment.
Spent on equipmentNot disclosedThis document does not carry the figure.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.